Innovent Biologics, Inc.
6IB.F·Frankfurt·Healthcare
9.37+0.22 (+2.42%)today
As of Oct 23, 9:55 AM CEST · May be delayed up to 15 min · EUR
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close9.15
Open9.37
Day range9.379.37
52-week range7.9112.10
Off day high−0.04%
Off 52-week high−22.54%
Volume10.00
Avg. volume (3M)275
Market cap16.34B
EPS (TTM)0.0800
Forward P/E—
P/E ratio (TTM)117.13
Dividend yield—
Beta (5Y)0.33
Shares outstanding1.74B
Short interest—
Earnings dateAug 25, 2026
Analyst target—
Profit margin7.85%
Against its peers
Compare in full ›| 6IB.F | ROIV | SMZ1.F | 9969.HK | 0A3M.IL | 1877.HK | |
|---|---|---|---|---|---|---|
| Market cap | 16.34B | 26.36B | 10.15B | 20.80B | 24.21B | 17.15B |
| P/E (TTM) | 117.1 | — | 28.5 | 19.6 | 4.9 | — |
| Forward P/E | — | -21.2 | — | 55.7 | 4.9 | 83.6 |
| Price/book | 5.9 | 6.2 | 2.3 | 2.3 | 1.1 | 2.5 |
| Dividend yield | — | — | 2.64% | — | — | — |
| 1-year change | −1.62% | +105.54% | −27.04% | −15.10% | −13.51% | −34.00% |
| Today | +2.42% | −2.56% | +3.45% | +0.17% | −3.56% | +1.09% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 6IB.F news ›Innovent Biologics announces approval of SYCUME in China for thyroid eye disease
The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s second, approved IGF-1R antibody drug. Innovent Biologics announced the approval of SYCUME, a recombinant…
From articles in the 4Search news index.
In the news
1mentions in 30 days
1with it in the headline
Positivesentiment
Mentioned with
People in the coverage
Most coverage from
-
prnewswire.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.